In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target

头颈癌体内 CRISPR 筛选揭示 Uchl5 可作为免疫治疗靶点

阅读:12
作者:Cong Fu ,Robert Saddawi-Konefka ,Jordan M Chinai ,Sarah Y Kim ,Ashwin V Kammula ,Jonathan J Perera ,Aiping Jiang ,Payal Tiwari ,Erin N Kistler ,Shiqi Tang ,Sarah M Luna ,Kayla J Colvin ,Juan Dubrot ,Seth Anderson ,Rachel A Fetterman ,Cun Lan Chuong ,Sarah K Lane-Reticker ,Collins K Cheruiyot ,Audrey J Muscato ,Zahra Alipour ,Douglas R Adkins ,Gabriel K Griffin ,Bradley E Bernstein ,Ann Marie Egloff ,Kathleen B Yates ,Rebecca D Chernock ,J Silvio Gutkind ,Ravindra Uppaluri ,Robert T Manguso

Abstract

Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with a significant unmet need for enhancing immunotherapy response given current modest efficacy. Here, we perform an in vivo CRISPR screen in an HNSCC mouse model to identify immune evasion genes. We identify several regulators of immune checkpoint blockade (ICB) response, including the ubiquitin C-terminal hydrolase 5 (UCHL5). Loss of Uchl5 in tumors increases CD8+ T cell infiltration and improved ICB responses. Uchl5 deficiency attenuates extracellular matrix (ECM) production and epithelial-mesenchymal-transition (EMT) transcriptional programs, which contribute to stromal desmoplasia, a histologic finding we describe as associated with reduced anti-PD1 response in human HNSCCs. COL17A1, a collagen highly and specifically expressed in HNSCC, mediates in part Uchl5-mediated immune evasion. Our findings suggest an unappreciated role for UCHL5 in promoting EMT in HNSCC and highlight ECM modulation as a strategy to improve immunotherapy responses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。